Creatinine, not just a diabetes diagnosis, should trigger SGLT2 inhibitor use in CKD, says Sandra Chaparro, MD.
Sandra Chaparro, MD
Advertisement
Sandra Chaparro, MD, director of Advanced Heart Failure at Miami Cardiac & Vascular Institute, part of Baptist Health South Florida.
Articles by Sandra Chaparro, MD
Sandra Chaparro, MD, discusses using obesity medications in patients with heart failure.
Sandra Chaparro, MD, makes the case for SGLT2 inhibitors across a broad spectrum of chronic kidney disease, even in patients without diabetes.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
What Comes Next: Taking on Unanswered Questions in Multiple Myeloma
2
Early-Life, Parental Factors May Help Explain Rising Early-Onset CRC Rates
3
COVID-19 May Follow A Different Seasonal Pattern Than Influenza, RSV
4
Treatment for Thyroid Eye Disease Approved by FDA
5